Breaking Finance News

Zacks Investment Research downgraded IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to Sell in a report released today.

Zacks Investment Research has downgraded IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to Sell in a report released on Thursday October 13, 2016.

Previously on 10/03/2016, Brean Capital reported on IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) increased the target price from $0.00 to $8.00. At the time, this indicated a possible upside of 2.76%.

Yesterday IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) traded -2.68% lower at $2.98. IPCI’s 50-day average is $2.06 and its two hundred day average is $1.86. With the last stock price close up 55.84% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 766,604 shares of the stock were exchanged, up from an average trading volume of 382,834

See Chart Below

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)

IntelliPharmaCeutics Intl Inc (USA) has a 52 week low of $1.41 and a 52 week high of $3.33 The company’s market cap is currently $0.

About IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)

IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It has developed several drug delivery systems and a pipeline of products and product candidates in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS). Its products include Focalin XR, Keppra XR, Effexor XR, Protonix, Seroquel XR, Lamictal XR, Pristiq, Oleptro, Coreg CR, OxyContin and Lyrica.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.